Celcuity Inc. (NASDAQ:CELC) stock surged on Monday after the company reported topline results from the PIK3CA wild-type ...

New clinical trial results reveal gedatolisib significantly improves progression-free survival in advanced HR+/HER2– breast ...

Celcuity Inc. (CELC) stock surged about 221% on Monday morning after the company announced that its experimental combination ...

Celcuity recently released positive results from its phase 3 VIKTORIA-1 trial, and is raising both debt and shares. Read what ...

We recently published These 10 Stocks are Winning Big. Celcuity Inc. (NASDAQ:CELC) is one of the best-performing stocks on ...

Celcuity shares skyrocketed to an all-time high when the biotech reported positive results from a Phase 3 trial of its ...

Upgraded Relay Therapeutics to a buy after valuation decline. Read more on RLAY's pipeline progress, financial health, and ...

The median OS was 34.9 months (95% CI, 28.8 to 40.0) in the palbociclib plus fulvestrant group and 28.0 months (95% CI, 23.6 to 34.6) in the placebo plus fulvestrant group.

Fulvestrant has demonstrated efficacy in the treatment of postmenopausal women with advanced, hormone-sensitive breast cancer, with data indicating that fulvestrant exhibits this activity in both ...

The Food and Drug Administration (FDA) has approved Truqap ™ (capivasertib) in combination with fulvestrant for the treatment of adults with hormone receptor (HR)-positive, human epidermal ...

PATIENTS AND METHODS: Patients (n = 451) with advanced breast cancer were randomized to receive fulvestrant 250 mg as a once-monthly (one × 5 mL) intramuscular injection or an oral dose of anastrozole ...